{"orpha":1909,"name":"Indomethacin embryofetopathy","type":"Malformation syndrome","group":"Disorder","status":"active","flags":[],"synonyms":["Fetal indomethacin syndrome"],"definition":"Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitis in preterm infants.","note":null,"url":"https://raremap.alftech.space/d/ORPHA-1909/","orphanet_url":"https://www.orpha.net/en/disease/detail/1909","names":{"fr":{"name":"Embryofoetopathie à l'indométacine","synonyms":["Exposition anténatale à l'indometacine"],"definition":"Manifestations qui peuvent être observées chez un foetus ou un nouveau-né dont la mère a pris de l'indométhacine, un puissant inhibiteur de la prostaglandine et un agent tocolytique qui peut traverser le placenta pendant la grossesse. Les effets indésirables signalés sur le foetus et le nouveau-né comprennent une insuffisance rénale entraînant un oligohydramnios, la fermeture du canal artériel et un retard d'adaptation cardiovasculaire à la naissance. Ces effets sont généralement transitoires et réversibles. L'indométacine peut également être un facteur de risque de lésions cérébrales (leucomalacie périventriculaire) et d'entérocolite nécrosante chez les prématurés."},"de":{"name":"Indometacin-Embryopathie","synonyms":["Indometacin-Exposition, vorgeburtliche","Indomethacin-Embryofetopathie"],"definition":"Indomethacin-Embryofetopathie bezeichnet die Symptome, die bei einem Fötus oder Neugeborenen auftreten können, wenn die Mutter während der Schwangerschaft Indomethacin eingenommen hat, einen starken Prostaglandinhemmer und Wehenhemmer, der die Plazenta passieren kann. Zu den berichteten unerwünschten Wirkungen bei Föten/Neugeborenen gehören eine verminderte Nierenfunktion, die zu Oligohydramnion führt, der Verschluss des Ductus arteriosus und eine verzögerte kardiovaskuläre Anpassung bei der Geburt. Diese Wirkungen sind in der Regel vorübergehend und reversibel. Indomethacin kann auch ein Risikofaktor für Hirnschäden (periventrikuläre Leukomalazie) und nekrotisierende Enterokolitis bei Frühgeborenen sein."},"es":{"name":"Embriopatía por indometacina","synonyms":["Exposición fetal a la indometacina"],"definition":"Este término hace referencia a las manifestaciones que pueden observarse en un feto o un recién nacido cuando la madre ha consumido indometacina durante la gestación. La indometacina es un potente inhibidor de la prostaglandina y un agente tocolítico que puede atravesar la placenta durante el embarazo. Entre los efectos adversos descritos en fetos y en neonatos se incluyen la disminución de la función renal que resulta en oligohidramnios, cierre del ductus arterioso y retraso en la adaptación cardiovascular tras el nacimiento. Estos efectos suelen ser transitorios y reversibles. La indometacina también puede constituir un factor de riesgo de lesión cerebral (leucomalacia periventricular) y de enterocolitis necrotizante en recién nacidos prematuros."},"it":{"name":"Embrio/fetopatia da indometacina","synonyms":["Esposizione prenatale all'indometacina"],"definition":"L'embrio/fetopatia da indometacina comprende una serie di segni clinici che si osservano nei feti o nei neonati le cui madri, durante la gravidanza, hanno assunto indometacina, un potente inibitore delle prostaglandine e un agente tocolitico che attraversa la placenta. Gli effetti avversi osservati nei feti/neonati comprendono la riduzione della funzionalità renale che esita nell'oligoidramnios, nella chiusura dei dotti arteriosi e in un ritardo dell'adattamento cardiovascolare alla nascita. Di solito questi effetti sono transitori e reversibili. L'indometacina costituisce inoltre un fattore di rischio per i danni cerebrali (leucomalacia periventricolare) e per l'enterocolite necrotizzante nei neonati pretermine."},"nl":{"name":"Indometacine-embryofoetopathie","synonyms":["Foetaal indometacinesyndroom"],"definition":"Indometacine-embryofoetopathie verwijst naar de manifestaties die mogelijk kunnen waargenomen worden bij een foetus of pasgeborene wanneer de moeder tijdens de zwangerschap indometacine heeft ingenomen, een potente inhibitor van prostaglandine en een tocolyticum dat de placenta kan passeren. Gerapporteerde nadelige foetale/neonatale effecten zijn onder meer verminderde nierfunctie met oligohydramnion tot gevolg, sluiting van de ductus arteriosus, en vertraagde cardiovasculaire adaptatie bij de geboorte. Deze effecten zijn doorgaans transiënt en omkeerbaar. Indometacine kan ook een risicofactor zijn voor cerebrale schade (periventriculaire leukomalacie) en necrotiserende enterocolitis bij prematuren."},"pt":{"name":"Embriofetopatia por indometacina","synonyms":["Síndrome indometacina fetal"]},"pl":{"name":"Embriofetopatia indometacynowa","synonyms":["Płodowy zespół indometacynowy"]},"cs":{"name":"Indometacinová embryofetopatie","synonyms":["Fetální indometacinový syndrom"]},"uk":{"name":"Індометацинова ембріофетопатія","synonyms":["Синдром індометацину у плода"],"definition":"Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants."},"zh":{"name":"吲哚美辛胚胎胎儿病","synonyms":["胎儿吲哚美辛综合征"]},"tr":{"name":"İndometasin embriyofetopatisi","synonyms":["fetal indometasin sendromu"]}},"xrefs":[{"source":"ICD-10","code":"Q86.8","qualifier":"NTBT","icd_relation":"attributed","validated":true},{"source":"ICD-11","code":"LD2F.0Y","qualifier":"NTBT","icd_relation":"index","validated":true,"icd11_uri":"1929563114"},{"source":"MONDO","code":"0016005","qualifier":"E","icd_relation":null,"validated":true},{"source":"UMLS","code":"C4275138","qualifier":"E","icd_relation":null,"validated":true}],"associations":[],"incoming_associations":[],"preferential_parent":{"orpha":93890,"name":"Rare developmental defect during embryogenesis"},"parents":[{"orpha":138059,"name":"Teratogenic Pierre Robin syndrome","classifications":[147,200,209]},{"orpha":251529,"name":"Toxic or drug-related embryofetopathy","classifications":[147,204,216]}],"children":[],"genes":[],"genes_via_subtypes":[],"inheritance":["Not applicable"],"onset":["Antenatal","Neonatal"],"prevalence":[{"type":"Point prevalence","qualification":"Class only","class":"Unknown","value":0.0,"area":"Worldwide","status":"Not yet validated","source":"ORPHANET"}],"phenotypes":{"validation_status":"y","online":"y","validation_date":"2016-06-01","source":null,"terms":[{"hpo":"HP:0000112","label":"Nephropathy","frequency":"Very frequent (99-80%)","criteria":null},{"hpo":"HP:0001622","label":"Premature birth","frequency":"Very frequent (99-80%)","criteria":null},{"hpo":"HP:0000083","label":"Renal insufficiency","frequency":"Very frequent (99-80%)","criteria":null},{"hpo":"HP:0002093","label":"Respiratory insufficiency","frequency":"Very frequent (99-80%)","criteria":null},{"hpo":"HP:0000091","label":"Abnormal renal tubule morphology","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001928","label":"Abnormality of coagulation","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001631","label":"Atrial septal defect","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001638","label":"Cardiomyopathy","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001789","label":"Hydrops fetalis","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0000003","label":"Multicystic kidney dysplasia","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001562","label":"Oligohydramnios","frequency":"Occasional (29-5%)","criteria":null},{"hpo":"HP:0001629","label":"Ventricular septal defect","frequency":"Occasional (29-5%)","criteria":null}]}}